Component,Publication Grant Number,Publication Doi,Publication Journal,Pubmed Id,Publication Title,Pubmed Url,Publication Year,Publication Keywords,Publication Authors,Publication Abstract,Publication Assay,Publication Tumor Type,Publication Tissue,Publication Dataset Alias,Publication Accessibility,PublicationView_id,Id,entityId,Dataset View_id
PublicationView,CA210181,10.1038/s41419-023-05834-9,Cell Death Dis,37169743,Interferon-gamma is quintessential for NOS2 and COX2 expression in ER<sup>-</sup> breast tumors that lead to poor outcome,https://pubmed.ncbi.nlm.nih.gov/37169743,2023,,"Robert Y S Cheng, Lisa A Ridnour, Adelaide L Wink, Ana L Gonzalez, Elise L Femino, Helene Rittscher, Veena Somasundaram, William F Heinz, Leandro Coutinho, M Cristina Rangel, Elijah F Edmondson, Donna Butcher, Robert J Kinders, Xiaoxian Li, Stephen T C Wong, Daniel W McVicar, Stephen K Anderson, Milind Pore, Stephen M Hewitt, Timothy R Billiar, Sharon A Glynn, Jenny C Chang, Stephen J Lockett, Stefan Ambs, David A Wink","A strong correlation between NOS2 and COX2 tumor expression and poor clinical outcomes in ER breast cancer has been established. However, the mechanisms of tumor induction of these enzymes are unclear. Analysis of The Cancer Genome Atlas (TCGA) revealed correlations between NOS2 and COX2 expression and Th1 cytokines. Herein, single-cell RNAseq analysis of TNBC cells shows potent NOS2 and COX2 indu(Read more on Pubmed)","Cell Culture, Scratch Assay, Invasion Assay, Single Cell RNA-Sequencing, Immunohistochemistry Staining Method","Breast Adenocarcinoma, Triple-Negative Breast Carcinoma",Breast,Not Applicable,Open Access,37169743,d4158b34-414c-44ff-b98f-8f267ceb7d16,syn52500360,37169743
PublicationView,CA210181,10.3390/genes14051008,Genes (Basel),37239368,The Interplay between T Cells and Cancer: The Basis of Immunotherapy,https://pubmed.ncbi.nlm.nih.gov/37239368,2023,"Cancer, T cells, Antibody, Vaccine, Signaling, Cell therapy, Crispr, Alterations, Car T/tcr T/til","Christina Chen, Xin Liu, Che-Yu Chang, Helen Y Wang, Rong-Fu Wang","Over the past decade, immunotherapy has emerged as one of the most promising approaches to cancer treatment. The use of immune checkpoint inhibitors has resulted in impressive and durable clinical responses in the treatment of various cancers. Additionally, immunotherapy utilizing chimeric antigen receptor (CAR)-engineered T cells has produced robust responses in blood cancers, and T cell receptor(Read more on Pubmed)",Immunotherapy,Pan-cancer,Not Applicable,Not Applicable,Open Access,37239368,f2de69e4-8358-49fe-af53-c6a68b74ade7,syn52500360,37239368
PublicationView,CA210181,10.1021/acsptsci.0c00183,ACS Pharmacol Transl Sci,33615177,Innate Immunity Plays a Key Role in Controlling Viral Load in COVID-19: Mechanistic Insights from a Whole-Body Infection Dynamics Model,https://pubmed.ncbi.nlm.nih.gov/33615177,2021,,"Prashant Dogra, Javier Ruiz-Ramírez, Kavya Sinha, Joseph D Butner, Maria J Peláez, Manmeet Rawat, Venkata K Yellepeddi, Renata Pasqualini, Wadih Arap, H Dirk Sostman, Vittorio Cristini, Zhihui Wang","Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a pathogen of immense public health concern. Efforts to control the disease have only proven mildly successful, and the disease will likely continue to cause excessive fatalities until effective preventative measures (such as a vaccine) are developed. To develop disease management strategies, a better understanding of SARS-CoV-2 patho(Read more on Pubmed)","Mathematical Modeling, Computational Modeling",Pan-cancer,Not Applicable,Not Applicable,Open Access,33615177,8eeb0d1b-961d-4325-9f87-1488cfa70674,syn52500360,33615177
PublicationView,CA210181,10.20517/ais.2022.38,Artif Intell Surg,37124705,Potential of artificial intelligence in the risk stratification for and early detection of pancreatic cancer,https://pubmed.ncbi.nlm.nih.gov/37124705,2023,"Artificial intelligence, Pancreatic cancer, Early Detection, Risk Prediction","Daniela R Tovar, Michael H Rosenthal, Anirban Maitra, Eugene J Koay","Pancreatic ductal adenocarcinoma (PDAC) is the third most lethal cancer in the United States, with a 5-year life expectancy of 11%. Most symptoms manifest at an advanced stage of the disease when surgery is no longer appropriate. The dire prognosis of PDAC warrants new strategies to improve the outcomes of patients, and early detection has garnered significant attention. However, early detection o(Read more on Pubmed)",Pending Annotation,Pending Annotation,Pending Annotation,,Restricted Access,37124705,f08aaef3-3ec7-45a9-a14c-4008461a7b5b,syn52500360,37124705
PublicationView,CA210181,10.1159/000530134,Liver Cancer,37593365,Definitive Liver Radiotherapy for Intrahepatic Cholangiocarcinoma with Extrahepatic Metastases,https://pubmed.ncbi.nlm.nih.gov/37593365,2023,,"Brian De, Rituraj Upadhyay, Kaiping Liao, Tiffany Kumala, Christopher Shi, Grace Dodoo, Joseph Abi Jaoude, Kelsey L Corrigan, Gohar S Manzar, Kathryn E Marqueen, Vincent Bernard, Sunyoung S Lee, Kanwal P S Raghav, Jean-Nicolas Vauthey, Ching-Wei D Tzeng, Hop S Tran Cao, Grace Lee, Jennifer Y Wo, Theodore S Hong, Christopher H Crane, Bruce D Minsky, Grace L Smith, Emma B Holliday, Cullen M Taniguchi, Albert C Koong, Prajnan Das, Milind Javle, Ethan B Ludmir, Eugene J Koay","Introduction: Tumor-related liver failure (TRLF) is the most common cause of death in patients with intrahepatic cholangiocarcinoma (ICC). Though we previously showed that liver radiotherapy (L-RT) for locally advanced ICC is associated with less frequent TRLF and longer overall survival (OS), the role of L-RT for patients with extrahepatic metastatic disease (M1) remains undefined. We sought to c(Read more on Pubmed)",Survival Analysis,Cholangiocarcinoma,Liver,Not Applicable,Open Access,37593365,841e8e60-58a5-42e3-aa5a-307983a3bbed,syn52500360,37593365
